Patent Application
20170000816
The present invention relates to a cross-linked polysaccharide gel composition used in cosmetics and medicine fields, and more particularly, to a hyaluronic acid gel composition having durability capable of maintaining durability for a long time within a living body without increasing a cross-linked bond rate by including a material having functions of decomposition inhibition and antioxidation of polysaccharide in cross-linked polysaccharide gel.
Polysaccharide is a complex of sugar in which monosaccharides are bonded through glycoside bond, and in particular, sodium hyaluronate is widely used in cosmetics and medicine fields.
Sodium hyaluronate is glycosaminoglycans present in the dermis layer, and a living body polymer material in which N-acetyl-D-glucosamine and D-glucuronic acid are connected by beta-1,3 glycosidic bond and the repeating units are linearly connected to each other.
In addition, sodium hyaluronate is a living body constituent that is found in a body fluid, eyeballs of a cow, a cockscomb, a buffer tissue of an animal, placenta, and so on, and in particular, present in a connective tissue and the skin at a high concentration.
In addition, since sodium hyaluronate can contain water of thousand times of its own weight, sodium hyaluronate is widely used as humectants of cosmetics of preventing dry of the skin. Further, in a skin care field, sodium hyaluronate is used as dermal filler or the like in wrinkle improvement, contour correction, or the like, as being inserted into a specific area to expand a soft tissue. Furthermore, since sodium hyaluronate has good viscoelasticity, biocompatibility and biodegradability, sodium hyaluronate is widely used in degenerative osteoarthristis medicine, scar medicine, eyeball surgery assistance, anti-agglutination agent for preventing agglutination between tissues after surgery, and so on, in addition to the skin care.
However, since natural hyaluronic acid (HA) is rapidly decomposed in a living body by hyaluronidase and free radicals and has a very short half-life period of about a day, in spite of excellence of such hyaluronic acid, the natural hyaluronic acid cannot be directly applied to a field that requires a long half-life period such as a wrinkle medicine field.
In order to overcome the above-mentioned disadvantages, various kinds of cross-linking technologies have been developed, many kinds of cross-linked hyaluronic acid fillers using these technologies are developed in Europe and US, and in recent years, several products have been released in Korea.
U.S. Pat. No. 4,582,865 discloses hyaluronic derivatives that are cross-linked using divinyl sulfone (DVS) as a cross-linking agent, and hydro gel thereof is released as a trade name of Hylaform. In addition, U.S. Pat. No. 5,827,937 discloses a method of manufacturing a hyaluronic acid derivative cross-linking material using multi-functional epoxy compounds as a cross-linking agent, and in the multi-functional epoxy compounds, restylene serving as hydro gel of a hyaluronic acid cross-linking material manufactured using 1,4-butanediol diglycidyl ether (BDDE) as a cross-linking agent is world-widely released as a tissue-enhancing filler under approval of FDA in US.
Such products are generated by bonding a hydroxy group of hyaluronic acid and a cross-linking agent. While durability of the products in the living body is increased in comparison with non-cross-linked hyaluronic acid, bio-durability is low, for example decomposition within 6 to 12 months, and so on.
Since most of the cross-linked hyaluronic acid fillers have durability of less than 1 year, attempts of increasing a cross-linking bond rate have been performed to increase the durability. However, since feeling of irritation is caused by high storage modulus, this method is restrictive.
Accordingly, in order to increase durability, instead of an increase in cross-linked bond rate, a polysaccharide gel composition capable of increasing durability while having a storage modulus similar to the skin should be developed.
An object of the present invention is to provide a cross-linked hyaluronic acid gel composition having a long-term durability in a living body by including a material having functions of polysaccharide decomposition inhibition and antioxidation of cross-linked polysaccharide gel without increasing a cross-linking bond rate.
Another object of the present invention is to provide a cross-linked hyaluronic acid gel composition having a long-term durability, in a cross-linked polysaccharide gel composition used in cosmetics and medicine fields, including ursolic acid having functions of decomposition inhibition and antioxidation of polysaccharide in the cross-linked polysaccharide gel without an increase in cross-linked bond rate.
In order to achieve the aforementioned objects, the present invention is directed to a hydro gel complex including ursolic acid in non-cross-linked or cross-linked hyaluronic acid.
In addition, according to the present invention, the hydro gel composition includes at least one of polysaccharide selected from the group consisting of hyaluronic acid, cellulose, chitosan, dextran, dextran sulfate, chondroitin, chondroitin sulfate, heparin, heparin sulfate and alginate.
In addition, according to the present invention, a molecular weight of the polysaccharide is 20,000 Dalton (Da) to 5,000,000 Dalton (Da).
In addition, according to the present invention, a concentration of the ursolic acid is 0.001 mM to 1 M.
In addition, according to the present invention, lidocaine is further provided.
According to the present invention, the cross-linked polysaccharide gel composition including the ursolic acid has good biocompatibility and provides excellent long-term durability in the living body while maintaining a storage modulus most similar to the skin when the composition is injected into the living body with no increase in storage modulus.
In addition, a composition into which lidocaine serving as a local anesthetic according to the present invention is added attenuates pains of a patient upon surgery.
In addition, the composition according to the present invention provides effects of removing or improving wrinkles of the skin and recovering the tissue in an area such as the nose, cheeks, lips, breasts, hips, a deep scar, or the like.
In addition, the composition according to the present invention is used as an agent for enlarging a man's symbol urologically and an anti-agglutination agent for preventing long-term agglutination after surgery, and used as a degenerative arthritis medicine serving as lubricant for improving and curing degenerative arthritis.
An embodiment of the present invention will be described in detail with reference to the accompanying drawings.
As shown, a cross-linked polysaccharide gel composition having long-term durability according to the present invention is constituted by a hydro gel composition in which ursolic acid is included in non-cross-linked or cross-linked polysaccharide.
More specifically, the composition of the present invention is constituted by at least one polysaccharide selected from the group consisting of hyaluronic acid, cellulose, chitosan, dextran, dextran sulfate, chondroitin, chondroitin sulfate, heparin, heparin sulfate and alginate, and a hydro gel composition including ursolic acid serving as a material having functions of decomposition inhibition and antioxidation of the polysaccharide.
The polysaccharide uses at least one or more selected from the group consisting of hyaluronic acid, cellulose, chitosan, dextran, dextran sulfate, chondroitin, chondroitin sulfate, heparin, heparin sulfate and alginate, preferably, hyaluronic acid.
A molecular weight of the polysaccharide used in the present invention is 20,000 Dalton to 5,000,000 Dalton, preferably, 500,000 Dalton to 3,000,000 Dalton.
The ursolic acid used in the present invention is a pentacyclic triterpenoid-based compound known as urson, prunol, micromerol, malol, and so on, which is widely distributed in medicinal plant, herb, or the like.
The ursolic acid is considered to have pharmacological inactivity for a long time, and the ursolic acid and the sodium ursolate (e.g. potassium or sodium ursolates) have been used as a surfactant in medicine, cosmetics and foods.
However, it has been found that both of the ursolic acid and the sodium ursolate have pharmacological activity when the ursolic acid is locally taken through more precise research.
The ursolic acid exhibits effectiveness in anti-inflammatory action, anti-cancer effect (skin cancer), and anti-bacterial effect. Similar to most of triterpenoids-based compound, the ursolic acid is a compound that can be easily found in plants, and an ingredient of various kinds of plants in which a phylogeny origin and a classification position are diversified.
The ursolic acid is separated from peels of fruits such as an apple, a pear, a cranberry, a plum, and so on. In addition, ursolic acid derivatives are plentiful in seaweeds.
The ursolic acid used in the present invention is an excellent material of increasing durability in a living body of the polysaccharide gel because the ursolic acid has two functions of a polysaccharide decomposition inhibition agent and an antioxidant through a function of antioxidation while suppressing decomposition of the polysaccharide.
A concentration of the ursolic acid used in the present invention is 0.01 mM to 1 M, preferably, 0.05 mM to 100mM, and more preferably, 0.1 mM to 10 mM.
In addition, according to the present invention, in order to reduce pains of a patient during surgery, lidocaine serving as local anesthetic may be added to the cross-linked polysaccharide gel composition including the ursolic acid.
The composition of the present invention may be used to remove or improve wrinkles of the skin clinically or cosmetically, or recover the tissue of the area such as the nose, cheeks, lips, breasts, hips, deep scars, or the like.
In addition, the composition may be used as an anti-agglutination agent used to enlarge a man's symbol clinically or prevent long-term agglutination after surgery, or a degenerative arthritis medicine serving as lubricant for improvement and curing of degenerative arthritis.
Hereinafter, the present invention will be described in detail with reference to the following examples. However, the following examples are provided to exemplify the present invention but the scope of the present invention is not limited thereto.
100 uL of PBS (pH 7.0) solution was added to 1 g of cross-linked hyaluronic acid filler (REVOLAX™, Across Co., Ltd.) having a concentration of 24 mg/mL of HA and a storage modulus (G′) or about 130 Pa, and then, agitated to be completely mixed.
100 uL of PBS (pH 7.0) solution into which 0.1 mM of ursolic acid was added was added to 1 g of cross-linked hyaluronic acid filler (REVOLAX™, Across Co., Ltd) having a concentration of 24 mg/mL of HA and a storage modulus (G′) of about 130 Pa, and then, agitated to be completely mixed.
100 uL of PBS (pH 7.0) solution into which 0.5 mM of ursolic acid was added was added to 1 g of cross-linked hyaluronic acid filler (REVOLAX™, Across Co., Ltd) having a concentration of 24 mg/mL of HA and a storage modulus (G′) of about 130 Pa, and then, agitated to be completely mixed.
100 uL of PBS (pH 7.0) solution into which 1 mM of ursolic acid was added was added to 1 g of cross-linked hyaluronic acid filler (REVOLAX™, Across Co., Ltd) having a concentration of 24 mg/mL of HA and a storage modulus (G′) of about 130 Pa, and then, agitated to be completely mixed.
100 uL of PBS (pH 7.0) solution into which 5 mM of ursolic acid was added was added to 1 g of cross-linked hyaluronic acid filler (REVOLAX™, Across Co., Ltd) having a concentration of 24 mg/mL of HA and a storage modulus (G′) of about 130 Pa, and then, agitated to be completely mixed.
100 uL of PBS (pH 7.0) solution into which 10 mM of ursolic acid was added was added to 1 g of cross-linked hyaluronic acid filler (REVOLAX™, Across Co., Ltd) having a concentration of 24 mg/mL of HA and a storage modulus (G′) of about 130 Pa, and then, agitated to be completely mixed.
In order to expect durability in a living body of the hyaluronic acid-ursolic acid complex according to the present invention, decomposition tests by a hyaluronic acid decomposition enzyme of the hyaluronic acid-ursolic acid complex of the comparative example 1 and the examples 1 to 5 have been performed.
The hyaluronic acid hydro gels of the comparative example 1 and the examples 1 to 5 were frozen and dried, and the frozen and dried samples of the same mass were put into 50 mL tubes. 6mL of PBS solution (pH 7.0) including 200 units of hyaluronic acid decomposition enzyme (hyaluronidase from Streptomyces hyalurolyticus, Sigma-Aldrich) was added. The mixture was heated at 90° C. for 10 minutes to inactivate the hyaluronic acid decomposition enzyme after reaction at 37° C. for 24 hours. 18mL of purified water was added and agitated, and then, centrifugally separated (4,000 rpm for 15 minutes). 1 mL of supernatant was put into an epp. tube and centrifugally separated (12,000 rpm for 5 minutes). An amount of N-acetylglucosamine (NAG) decomposed and emitted from the centrifugally separated supernatant was measured through analysis according to a carbazole method. Decomposition levels of the cross-linked material are shown in the following Table 1.
As shown in Table 1, it has been found that decomposition of the cross-linked hyaluronic acid is affected by a concentration of the ursolic acid. It has been observed that decomposition of the cross-linked hyaluronic acid by the hyaluronic acid decomposition enzyme (hyaluronidase) is remarkably decreased as the concentration of the ursolic acid is increased.
In addition, when the concentration of the ursolic acid is 10 mM, little decomposition of the cross-linked hyaluronic acid by the hyaluronic acid decomposition enzyme (hyaluronidase) occurs. When the concentration of the ursolic acid is adjusted based on this, the hyaluronic acid hydro gel filler having desired durability can be manufactured.
In order to expect durability in the living body of the hyaluronic acid-ursolic acid complex according to the present invention, decomposition tests by free radicals of the hyaluronic acid-ursolic acid complex of the comparative example 1 and the examples 1 to 5 were performed.
The hyaluronic acid hydro gels of the comparative example 1 and the examples 1 to 5 are frozen and dried, and the frozen and dried samples of the same amount were put into 50 mL tubes.
6 mL of PBS solution (pH 7.0) including free radicals (a mixture of 0.2 mM of ascorbic acid and 0.2 mM of hydrogen peroxide) was added. 18 mL of purified water was added and agitated, and then, centrifugally separated (4,000 rpm for 15 minutes). 1 ml of a supernatant was put into the epp. tube to be centrifugally separated (12,000 rpm for 5 minutes).
An amount of N-acetylglucosamine (NAG) decomposed and emitted from the centrifugally separated supernatant was measured through analysis according to a carbazole method. Decomposition levels of the cross-linked material are shown in the following Table 2.
As shown in Table 2 and
In addition, when the concentration of the ursolic acid is 10 mM, little decomposition of the cross-linked hyaluronic acid by the free radicals occurs. When the concentration of the ursolic acid is adjusted based on this, the hyaluronic acid hydro gel filler having desired durability can be manufactured.
In order to estimate rheology characteristics of the present invention, a storage modulus (G′), a loss modulus (G″) and a degree of elasticity (%) of the hyaluronic acid-ursolic acid complex of the comparative example 1 and the examples 1 to 5 were measured using Rheometer (T.A. Instruments Ltd., USA). The test was performed within a range of 0.01 to 10 Hz using a 40 mm 2° cone-plate geometer at 25° C., and the storage modulus (G′) and the loss modulus (G″) were measured at 1.0 Hz. The degree of elasticity (%) was measured using the following equation, and resultant values are shown in the following table 3.
Percentage elasticity (%)=(G′/G′+G″)×100
As shown in Table 3 and
In order to estimate the squeeze force of the present invention, squeeze force tests of the hyaluronic acid-ursolic acid complex of the comparative example 1 and the examples 1 to 5 were performed using a squeeze force tester.
A glass syringe in which test liquid to be measured was put was inserted into a jig, and then, a push rod of the glass syringe was adjusted to be disposed at a center of a pressing plate. A tray (a Petri dish) was installed such that the test liquid is stuck to the jig, and then, squeeze force measurement was performed at a speed of 12 mm/min.
From the measured result, a point of 5 mm after application of a force was designated as a bottom marker position and a point of 5 mm forward from the measurement-terminated point was designated as a top marker position, and then, an average value therebetween was taken. The squeeze force values are shown in the following table 4.
As shown in Table 4 and
| Number | Date | Country | Kind |
|---|---|---|---|
| 10-2013-0152585 | Dec 2013 | KR | national |
| Filing Document | Filing Date | Country | Kind |
|---|---|---|---|
| PCT/KR2014/011912 | 12/5/2014 | WO | 00 |
